Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Lancet Oncology

• Publication date

  2012-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(12)70431-XPMID 23051966
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

  2012cited by this paper
• Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

  2012cited by this paper
• NRAS mutation status is an independent prognostic factor in metastatic melanoma

  2012cited by this paper
• Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases

  2012cited by this paper
• A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.

  2012cited by this paper
• Treatment of Melanoma Brain Metastases: A New Paradigm

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

  2012cited by this paper
• Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• The biology of brain metastases—translation to new therapies

  2011cited by this paper
• An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.

  2011cited by this paper
• A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors

  2011cited by this paper
• Prognostic factors for survival in melanoma patients with brain metastases

  2011cited by this paper
• Frequency of mutations associated with targeted therapy in malignant melanoma patients.

  2011cited by this paper
• Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma

  2011cited by this paper
• Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.

  2011cited by this paper
• Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need

  2011cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Final version of 2009 AJCC melanoma staging and classification.

  2009cited by this paper
• Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B‐RafV600E mutation

  2009cited by this paper
• Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.

  2008cited by this paper
• Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma

  2007cited by this paper
• Determinants of outcome in melanoma patients with cerebral metastases.

  2004cited by this paper
• Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.

  2004cited by this paper
• A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

  2003cited by this paper

• Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions.

  2026cites this paper
• Fractionated Stereotactic Radiotherapy to Resection Cavities Following Brain Metastasis Surgery: Clinical Outcomes and Challenges

  2026cites this paper
• Harnessing Oncolytic Viruses for Targeted Therapy in Triple-Negative Breast Cancer

  2025cites this paper
• Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases.

  2025cites this paper
• Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study

  2025influential citation
• Impact and diagnostic accuracy of 18F-FDG PET/CT in malignant melanoma staging and restaging: First Tunisian clinical report

  2025cites this paper
• Therapy-Induced Metastatic Melanoma During Treatment With Encorafenib and Cetuximab for BRAF-Mutated Colorectal Cancer: A Case Report and Short Literature Review.

  2025cites this paper
• The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis

  2025influential citation
• A Review on Melanoma Brain Metastases.

  2025cites this paper
• Molecular drivers in CNS metastatic disease.

  2025cites this paper
• Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.

  2025cites this paper
• Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study

  2025cites this paper
• Precision medicine approaches to CNS metastatic disease.

  2025cites this paper
• Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025

  2025cites this paper
• Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project

  2025cites this paper
• Successful response in advanced leptomeningeal disease from pleomorphic xanthoastrocytoma with BRAF/MEK inhibitors: a case report

  2025cites this paper
• Evolving treatment paradigms for melanoma brain metastases: A systematic review of current modalities.

  2025cites this paper
• Systemic treatment for a young patient with stage IV melanoma: A case report

  2025cites this paper
• Single-cell transcriptomics profiling reveals cellular origins and molecular drivers underlying melanoma brain metastasis

  2025cites this paper
• Protocatechuic aldehyde sensitizes BRAF-mutant melanoma cells to temozolomide through inducing FANCD2 degradation

  2025cites this paper
• Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204

  2025cites this paper
• First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China

  2025cites this paper
• High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study

  2025cites this paper
• Bilateral Cerebellopontine Angle Masses in a 72-Year-Old Woman With Prior Malignant Melanoma and a Cochlear Implant: A Diagnostic and Management Challenge

  2025influential citation
• Intracranial metastases from solid tumors: Call to Action and Consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology Collaborative.

  2025cites this paper
• Evolutionary Trend Analysis of Research on Immunotherapy for Brain Metastasis Based on Machine-Learning Scientometrics

  2024cites this paper
• Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review

  2024cites this paper
• A Comprehensive Review of Targeting RAF Kinase in Cancer Targeting RAF Kinase in Cancer.

  2024cites this paper
• European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.

  2024cites this paper
• Patterns of brain metastases response to immunotherapy with pembrolizumab

  2024cites this paper
• A Comprehensive Revision of Radiation Immunotherapy and the Abscopal Effect in Central Nervous System Metastases: Reassessing the Frontier

  2024cites this paper
• “Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools

  2024cites this paper
• Brain Metastases in Differentiated Thyroid Cancer: Clinical Presentation, Diagnosis, and Management

  2024cites this paper
• Melanoma Brain Metastasis: Biology and Therapeutic Advances.

  2024cites this paper
• Navigating the Complexities of Brain Metastases Management.

  2024cites this paper
• Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review.

  2024cites this paper
• Local and Systemic Management Options for Melanoma Brain Metastases.

  2024cites this paper
• The evolving landscape of tissue‐agnostic therapies in precision oncology

  2024cites this paper
• Clinical Practice Guidelines for Brain Metastasis From Solid Tumors

  2024cites this paper
• Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

  2024cites this paper
• Melanoma Brain Metastases: Immunotherapy or Targeted Therapy? A Systematic Review and Meta-Analyses

  2024cites this paper
• Local control and toxicity after stereotactic radiotherapy in brain metastases patients and the impact of novel systemic treatments.

  2024cites this paper
• Diagnostic and Therapeutic Particularities of Symptomatic Melanoma Brain Metastases from Case Report to Literature Review

  2024cites this paper
• Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma.

  2024cites this paper
• Delayed and Concurrent Stereotactic Radiosurgery in Immunotherapy-Naïve Melanoma Brain Metastases

  2024cites this paper
• Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib

  2024influential citation
• Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma

  2024cites this paper
• A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.

  2024cites this paper
• Very early symptomatic metastasis pseudoprogression after stereotactic brain radiosurgery in a melanoma patient treated with BRAF/MEK inhibitors: a case report and review of the literature

  2024cites this paper
• Predictive value of peripheral blood leukocytes-based methylation of Long non-coding RNA MALAT1 and H19 in the chemotherapy effect and prognosis of gastric cancer

  2024cites this paper
• Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases

  2023cites this paper
• Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

  2023cites this paper
• Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis

  2023cites this paper
• Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution

  2023cites this paper
• Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data

  2023cites this paper
• The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics

  2023cites this paper
• Management of Brain Metastases: A Review of Novel Therapies

  2023cites this paper
• Brain Metastases and Leptomeningeal Disease

  2023cites this paper
• A single‐center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan

  2023cites this paper
• Acquired and intrinsic resistance to vemurafenib in BRAFV600E ‐driven melanoma brain metastases

  2023influential citation
• Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS

  2023influential citation
• Efficacy, Safety, and Health-Related Quality of Life with Camrelizumab Plus Pemetrexed and Carboplatin as First-Line treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer with Brain Metastases (CAP-BRAIN): A Multicentre, Open-Label, Single-Arm, Phase 2 Study.

  2023cites this paper
• Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

  2023cites this paper
• Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases

  2023cites this paper
• Computational Investigations on Reaction Mechanisms of the Covalent Inhibitors Ponatinib and Analogs Targeting the Extracellular Signal-Regulated Kinases

  2023cites this paper
• TME-targeted approaches of brain metastases and its clinical therapeutic evidence

  2023cites this paper
• Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

  2023cites this paper
• Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications

  2023cites this paper
• Current status and perspectives of interventional clinical trials for brain metastases: analysis of ClinicalTrials.gov

  2023cites this paper
• PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis

  2023cites this paper
• BRAF Landscape and Its Implications among Patients with Pediatric Low-Grade Gliomas: A Comprehensive Review of the Literature

  2023cites this paper
• Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase

  2023cites this paper
• Amino Acid PET in Neurooncology

  2023cites this paper
• Successes and challenges in modeling heterogeneous BRAFV600E mutated central nervous system neoplasms

  2023cites this paper
• Combination toripalimab and bevacizumab for an elderly urothelial carcinoma patient with brain metastasis who failed rapidly after radiotherapy: a case report and literature review

  2022cites this paper
• Changes in outcomes and factors associated with survival in melanoma patients with brain metastases

  2022cites this paper
• Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.

  2022cites this paper
• Acquired and intrinsic resistance to vemurafenib in BRAFV600E-driven melanoma brain metastases

  2022cites this paper
• Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma

  2022cites this paper
• BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis

  2022cites this paper
• Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases

  2022cites this paper
• Melanoma classification and management in the era of molecular medicine.

  2022cites this paper
• Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

  2022cites this paper
• Current and emerging options for patients with melanoma brain metastases.

  2022cites this paper
• CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells

  2022cites this paper
• Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors

  2022cites this paper
• Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer

  2022cites this paper
• Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience

  2022cites this paper
• Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st‐line BRAF‐targeted therapy

  2022cites this paper
• Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival.

  2022cites this paper
• Primary Intracranial Brainstem Malignant Melanoma: A Technical Case Report

  2022cites this paper
• Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

  2022cites this paper
• In Patients With Melanoma Brain Metastases, Is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic

  2022cites this paper
• Target-Agnostic P-Glycoprotein Assessment Yields Strategies to Evade Efflux, Leading to a BRAF Inhibitor with Intracranial Efficacy.

  2022cites this paper
• The role of systemic therapy in melanoma brain metastases: a narrative review.

  2022cites this paper
• Mutational status and clinical outcomes following systemic therapy with or without focal radiation for resected melanoma brain metastases.

  2022cites this paper
• A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib

  2022influential citation
• Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)

  2022cites this paper
• Liquid biopsies to occult brain metastasis

  2022cites this paper
• Zerebrale Metastasen: Herausforderungen der Systemtherapie

  2022cites this paper